MedTrace Logo

Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy

NCT03039062 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2017-03-30

No results posted yet for this study

Summary

This is an open , multicenter, interventional clinical trial to conform the role of of miR-122 a real-time detection biomarker of drug-induced liver injury by chemotherapy.

Conditions

  • Chemotherapeutic Toxicity
  • Malignant Tumor
  • Liver Injury

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Binghe Xu, MD,PHD · Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039062 on ClinicalTrials.gov